News Over Recent Invokana Lawsuit Draws Public Attention To Potential Heart Attack Dangers

March 28, 2016 – – TheProductLawyers.com notes recent reports of increased heart attack risk indications within the first 30 days of treatment for patients using new-generation, type-2 diabetes drug Invokana. These indications were reportedly seen during clinical trials, which seemed to link the SGLT2 class inhibitor drug to certain heart issues among patients taking it.

In March of 2013, Invokana gained approval by the U.S. Food and Drug Administration, when it was the first of a group of similar diabetes drugs called SGLT2 inhibitors to be released to market. It was reported that during clinical trials conducted on Invokana, 13 patients were noted to have suffered from strokes, heart attacks, or other major cardiac events, specifically within the first 30 days of their treatment. It was also reported, however, that after this 30 day risk period, the risk for these events suddenly equalized among patients using Invokana when compared to patients taking simply a placebo pill.

The New York Times discussed these risks in an article, noting, “The label of the drug includes no warnings about heart attacks or strokes. …The FDA is requiring Johnson & Johnson to conduct five post-marketing studies, including a clinical trial to determine more definitively if the drug increases those risks.”

Unfortunately, Invokana is not the first diabetes drug to have been connected to heart attack risks. A drug called Avandia was reportedly linked to an increased heart attack risk in 2010, and was fully banned in Europe as well as tightly restricted across the United States. Invokana, as well, has been reported to potentially increase cholesterol, though researchers say that they are unsure at this time if this is actually the root of the problem observed in patients during the first month of clinical trials. It should be noted, however, that diabetes patients, in general, have been deemed at increased risk of heart disease and stroke because of their condition. In addition, heart attack occurrences are markedly more serious among diabetes patients.

A heart attack happens to a patient when blood flow to their heart is somehow restricted. In general, this is caused by blood clots. Without blood flow (and, therefore, oxygen,) the heart muscle begins to die. When this happens, the tissue is damaged, and if enough damage is sustained, the heart muscle can be prevented from pumping blood throughout the patient’s body.

The attorneys of Banville Law understand how concerning this potential side effect information may be to patients currently taking Invokana or other similar drugs. They are dedicated to keeping consumers informed of the most current information surrounding these and other drugs. To accomplish this, they sponsor the resource website TheProductLawyers.com. Additionally, they are working to assist patients who have taken Invokana and have also suffered from adverse events that they believe were caused by their use of the drug. These patients may be entitled to compensation and legal action. Those affected who wish to look into legal options are now offered free consultations by Banville Law.

To ask questions regarding Invokana lawsuits, or to request additional information, please contact the attorneys of Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008913